Repurposed drugs for COVID-19: threshold and proof requirements for trials.

Paul, Mical; Kalil, Andre C

Paul, Mical; Kalil, Andre C.

Paul M; Division of Infectious Diseases, Rambam Health Care Campus and The Ruth and Bruce Rappaport, Technion-Israel Institute of Technology, Israel. Electronic address: paulm@technion.ac.il.
Kalil AC; Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Clin Microbiol Infect ; 27(12): 1716-1717, 2021 12.

Article in English | MEDLINE | ID: covidwho-1433089

Subject(s)

COVID-19; Pharmaceutical Preparations; Antiviral Agents/therapeutic use; Drug Repositioning; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmaceutical Preparations / COVID-19 Limits: Humans Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google